The Impact of Cefuroxime Susceptibility on Aeromonas Necrotizing Fasciitis Outcomes
- PMID: 38004787
- PMCID: PMC10673460
- DOI: 10.3390/microorganisms11112776
The Impact of Cefuroxime Susceptibility on Aeromonas Necrotizing Fasciitis Outcomes
Abstract
Despite aggressive antibiotic therapy and surgical debridement, Aeromonas necrotizing fasciitis (NF) can lead to high amputation and mortality rates. Our study compares the different antibiotic minimum inhibitory concentrations (MICs) via Epsilometer tests (E-tests) between non-survivors and survivors of Aeromonas NF of limbs. A prospective review of 16 patients with Aeromonas NF was conducted for 3.5 years in a tertiary coastal hospital. E-tests were conducted for 15 antimicrobial agents to determine the MIC value for Aeromonas species. These patients were divided into non-survival and survival groups. The clinical outcomes, demographics, comorbidities, presenting signs and symptoms, laboratory findings, and microbiological results between the two periods were compared. A total of four patients died, whereas 12 survived, resulting in a 25% mortality rate. A higher proportion of bloodstream infections (100% vs. 41.7%; p = 0.042), monomicrobial infections (100% vs. 33.3%; p = 0.021), shock (100% vs. 33.3%; p = 0.021), serous bullae (50% vs. 0%; p = 0.009), liver cirrhosis (100% vs. 25%; p = 0.009), chronic kidney disease (100% vs. 33.3%; p = 0.021), lower susceptibility to cefuroxime (25% vs. 83.3%; p = 0.028), and ineffective antibiotic prescriptions (75% vs. 16.7%; p = 0.029) was observed in non-survivors. Aeromonas NF is an extremely rare skin and soft-tissue infection that is associated with high mortality, bacteremia, antibiotic resistance, and polymicrobial infection. Therefore, antibiotic regimen selection is rendered very challenging. To improve clinical outcomes and irrational antimicrobial usage, experienced microbiologists can help physicians identify specific pathogens and test MIC.
Keywords: Aeromonas; and minimum inhibitory concentrations; antimicrobial susceptibility; necrotizing fasciitis.
Conflict of interest statement
The authors declare that they have no competing interest.
Figures
Similar articles
-
Independent Predictors of Mortality for Aeromonas Necrotizing Fasciitis of Limbs: An 18-year Retrospective Study.Sci Rep. 2020 May 7;10(1):7716. doi: 10.1038/s41598-020-64741-7. Sci Rep. 2020. PMID: 32382057 Free PMC article.
-
Rational Use of Antibiotics and Education Improved Aeromonas Necrotizing Fasciitis Outcomes in Taiwan: A 19-Year Experience.Antibiotics (Basel). 2022 Dec 8;11(12):1782. doi: 10.3390/antibiotics11121782. Antibiotics (Basel). 2022. PMID: 36551439 Free PMC article.
-
Comparison of Surgical Outcomes and Predictors in Patients with Monomicrobial Necrotizing Fasciitis and Sepsis Caused by Vibrio vulnificus, Aeromonas hydrophila, and Aeromonas sobria.Surg Infect (Larchmt). 2022 Apr;23(3):288-297. doi: 10.1089/sur.2021.337. Epub 2022 Feb 18. Surg Infect (Larchmt). 2022. PMID: 35180367
-
Monomicrobial Klebsiella pneumoniae necrotizing fasciitis: an emerging life-threatening entity.Clin Microbiol Infect. 2019 Mar;25(3):316-323. doi: 10.1016/j.cmi.2018.05.008. Epub 2018 May 19. Clin Microbiol Infect. 2019. PMID: 29787886 Review.
-
Massive soft tissue infections: necrotizing fasciitis and purpura fulminans.J Long Term Eff Med Implants. 2005;15(1):57-65. doi: 10.1615/jlongtermeffmedimplants.v15.i1.70. J Long Term Eff Med Implants. 2005. PMID: 15715517 Review.
Cited by
-
Clinical characteristics and antibiotic sensitivity & resistance analysis of cases of orthopedic infections caused by Aeromonas hydrophila.BMC Musculoskelet Disord. 2025 Jun 5;26(1):560. doi: 10.1186/s12891-025-08806-6. BMC Musculoskelet Disord. 2025. PMID: 40474108 Free PMC article.
References
Grants and funding
LinkOut - more resources
Full Text Sources